Sunifiram

Sunifiram
Legal status
Legal status	US: Not FDA approved; unscheduled;
Identifiers
	IUPAC name 1-Benzoyl-4-propanoylpiperazine;
CAS Number	314728-85-3 ;
PubChem CID	4223812;
ChemSpider	3432996 ;
UNII	66924E735K;
ChEMBL	ChEMBL309176 ;
CompTox Dashboard (EPA)	DTXSID10400996 ;
Chemical and physical data
Formula	C14H18N2O2
Molar mass	246.304 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(=O)N1CCN(CC1)C(=O)c2ccccc2;
	InChI InChI=1S/C14H18N2O2/c1-2-13(17)15-8-10-16(11-9-15)14(18)12-6-4-3-5-7-12/h3-7H,2,8-11H2,1H3 ; Key:DGOWDUFJCINDGI-UHFFFAOYSA-N ;
	(what is this?) (verify)

Sunifiram (DM-235) is a piperazine derived research chemical which has anti-amnesiac effects in animal studies with significantly higher potency than piracetam.^[1] Sunifiram is a molecular simplification of unifiram.^[2] The anti-amnesiac effect of sunifiram and unifiram has been shown to involve AMPA-receptor activation.^[3]

As of 2017 it had not been subjected to toxicology testing, nor to any human clinical trials, and is not approved for use anywhere in the world.^[1]

References

^ ^a ^b Gualtieri F (2016). "Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings". Journal of Enzyme Inhibition and Medicinal Chemistry. 31 (2): 187–94. doi:10.3109/14756366.2015.1021252. PMID 25831025.
^ Manetti, D.; Ghelardini, C.; Bartolini, A.; Dei, S.; Galeotti, N.; Gualtieri, F.; Romanelli, M. N.; Teodori, E. (2000). "Molecular simplification of 1,4-diazabicyclo4.3.0nonan-9-ones gives piperazine derivatives that maintain high nootropic activity". Journal of medicinal chemistry. 43 (23): 4499–4507. doi:10.1021/jm000972h. PMID 11087574.
^ Galeotti, N.; Ghelardini, C.; Pittaluga, A.; Pugliese, A.; Bartolini, A.; Manetti, D.; Romanelli, M.; Gualtieri, F. (2003). "AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram)". Naunyn-Schmiedeberg's archives of pharmacology. 368 (6): 538–545. doi:10.1007/s00210-003-0812-6. PMID 14600801.

Template:Nootropics

[Gualtieri2016rev-1] Gualtieri F (2016). "Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings". Journal of Enzyme Inhibition and Medicinal Chemistry. 31 (2): 187–94. doi:10.3109/14756366.2015.1021252. PMID 25831025.

[2] Manetti, D.; Ghelardini, C.; Bartolini, A.; Dei, S.; Galeotti, N.; Gualtieri, F.; Romanelli, M. N.; Teodori, E. (2000). "Molecular simplification of 1,4-diazabicyclo4.3.0nonan-9-ones gives piperazine derivatives that maintain high nootropic activity". Journal of medicinal chemistry. 43 (23): 4499–4507. doi:10.1021/jm000972h. PMID 11087574.

[3] Galeotti, N.; Ghelardini, C.; Pittaluga, A.; Pugliese, A.; Bartolini, A.; Manetti, D.; Romanelli, M.; Gualtieri, F. (2003). "AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram)". Naunyn-Schmiedeberg's archives of pharmacology. 368 (6): 538–545. doi:10.1007/s00210-003-0812-6. PMID 14600801.

[1]

[2]

[3]